SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
Globe Newswire•29/10/2026•08:30 ET
0
Key Highlights
- ➤SAB Biotherapeutics will report third-quarter 2026 financial results November 5, 2026
- ➤Management will host an earnings call and webcast at 08:30 AM ET
- ➤Lead candidate SAB-142 is being evaluated in Phase 2b and Phase 3 trials
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial results will be issued on the morning of Thursday, November 5, 2026. Management will host a conference call and webcast at 08:30 AM ET to discuss the results and provide business updates.
To access the live conference call, participants may register here.
Get started
Create a free account to read the full story.